BPG is committed to discovery and dissemination of knowledge
Featured Articles
12/26/2018 3:14:34 AM | Browse: 697 | Download: 1732
Publication Name World Journal of Diabetes
Manuscript ID 40441
Country Japan
Received
2018-06-25 00:04
Peer-Review Started
2018-06-25 03:23
First Decision by Editorial Office Director
2018-07-09 03:56
Return for Revision
2018-07-11 01:59
Revised
2018-07-12 09:41
Publication Fee Transferred
Second Decision by Editor
2018-08-22 07:00
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director
2018-08-26 23:46
Articles in Press
2018-08-26 23:46
Edit the Manuscript by Language Editor
Typeset the Manuscript
2018-10-09 02:55
Publish the Manuscript Online
2018-10-12 11:58
ISSN 1948-9358 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Endocrinology & Metabolism
Manuscript Type Retrospective Cohort Study
Article Title Efficacy of anagliptin as compared to linagliptin on metabolic parameters over 2 years of drug consumption: A retrospective cohort study
Manuscript Source Invited Manuscript
All Author List Hidetaka Hamasaki and Yasuteru Hamasaki
Funding Agency and Grant Number
Corresponding Author Hidetaka Hamasaki, MD, PhD, Doctor, Doctor, Endocrinology and Metabolism, Internal Medicine, Hamasaki Clinic, 2-21-4 Nishida, Kagoshima 8900046, Japan. hhamasaki78@gmail.com
Key Words Type 2 diabetes mellitus; Dipeptidyl pep­tidase-4 inhibitor; Anagliptin; Linagliptin; Cholesterol
Core Tip Whether a substantial clinical difference exists in the effect of dipeptidyl peptidase-4 (DPP-4) inhibitors on metabolic parameters remains inconclusive. Although this study is a relatively small-scale, short duration, retrospective study, the findings of this study suggests that the efficacy of DPP-4 inhibitors on the blood pressure, lipid profile, and liver function differs between anagliptin and linagliptin.
Publish Date 2018-10-12 11:58
Citation Hamasaki H, Hamasaki Y. Efficacy of anagliptin as compared to linagliptin on metabolic parameters over 2 years of drug consumption: A retrospective cohort study. World J Diabetes 2018; 9(10): 165-171
URL http://www.wjgnet.com/1948-9358/full/v9/i10/165.htm
DOI http://dx.doi.org/10.4239/wjd.v9.i10.165
Full Article (PDF) WJD-9-165.pdf
Full Article (Word) WJD-9-165.doc